According to the Zhitong Finance App, Medical Connect (02192) announced that the board of directors expects a significant increase in profits due to parent company owners in the first half of 2023, up to no less than RMB 90 million from the same period in 2022.
The board of directors believes that the increase in revenue from precision marketing and corporate solutions in the Group's core business is mainly due to the return to normal hospital diagnosis and treatment after the pandemic, the acceleration of the approval process for new drugs, and the accelerated recovery of product sales and marketing work for pharmaceutical and medical device company customers. The precise marketing and enterprise solutions provided by the Group meet market needs, help customers achieve doctor coverage around the entire life cycle of pharmaceutical products, conduct doctors' academic education in a compliant, accurate and efficient manner, and have been widely recognized by pharmaceutical and medical equipment company customers. As a result, the number of medical customers purchasing the Group's precision marketing and enterprise solutions and the number of medical customer products using the Group's precision marketing and enterprise solutions continued to grow in the first half of 2023.
In addition to the above, the increase in profit due to parent company owners in the first half of 2023 was due to the positive impact of the Group's effective control of sales and distribution expenses and administrative expenses and interest rates in the bank deposit market.